Abstract: The present invention relates to the field of the treatment and/or prevention of viral infection caused by SARS-CoV-2. The inventor found that N-(2(quinolyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone was able to inhibit SARS-CoV-2 replication both in vitro and in vivo and that this inhibition was more important compared to the one obtained with the non-O-methylated form of this compound (quinolyl-valyl-aspartyl-[-2,6-difluorophenoxy]-methyl ketone). Thus the present invention concerns the N-(2(quinolyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone or a pharmaceutically acceptable salt or solvate thereof for use in preventing and/or treating a viral infection caused by SARS-CoV-2. The present invention also concerns a pharmaceutical composition and a kit of parts comprising such a compound for the same use.

Abstract: The use of the HIP/PAP protein or a protein derivative thereof for manufacturing a medicament for preventing or treating: a neonatal brain injury, which includes a neonatal brain injury caused by a brain hypoxia, an adult or child brain injury, which includes an adult or child brain injury caused by a brain hypoxia, an adult or child or neonatal traumatic brain injury, a cerebellar disease or disorder, and a disease involving a defect in the production or in the phosphorylation of Gap-43.

Abstract: A peroxisome-associated polypeptide and a nucleotide sequence encoding the peroxisome-associated polypeptide are disclosed. The protein is useful in the diagnosis and/or treatment of several diseases, particularly lung injuries and diseases as well as oxidative stress-related disorders, particularly neurotoxic injury or exitotoxic injury.